Literature DB >> 879748

Penetration of cefazolin into pleural fluid.

D R Cole, J Pung.   

Abstract

Single doses of cefazolin, 500 mg intramuscularly and 1 g intravenously, were administered to 16 patients having lung pathology who were scheduled for thoracic fluid aspiration. Pleural fluid and serum samples were taken at intervals of 30 to 240 min for determination of cefazolin levels. The levels obtained were variable; however, the levels of cefazolin in pleural fluid generally exceeded the reported minimal inhibitory concentration values for Staphylococcus pneumoniae and Staphylococcus, and group A beta-hemolytic streptococcus. In addition, the pleural fluid levels exceeded the minimal inhibitory concentration for cefazolin against most of the Klebsiella and Haemophilus influenzae strains. These data show that cefazolin, despite its comparative high protein binding, produces levels in the pleural fluid capable of inhibiting the organisms commonly found in respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 879748      PMCID: PMC352124          DOI: 10.1128/AAC.11.6.1033

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  CEPHALOTHIN: ACTIVITY IN VITRO, ABSORPTION AND EXCRETION IN NORMAL SUBJECTS AND CLINICAL OBSERVATIONS IN 40 PATIENTS.

Authors:  J O KLEIN; T C EICKHOFF; J G TILLES; M FINLAND
Journal:  Am J Med Sci       Date:  1964-12       Impact factor: 2.378

2.  In vitro studies with cefazolin.

Authors:  M Motley; S Shadomy
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

3.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  The penetration of cephalothin into synovial and other body fluids.

Authors:  D W Gump; R L Lipson
Journal:  Curr Ther Res Clin Exp       Date:  1968-11

5.  Cefazolin in the treatment of bacterial pneumonia.

Authors:  M Turck; R A Clark; H N Beaty; K K Holmes; W W Karney; L B Reller
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Hemophilus influenzae type B susceptibility to 17 antibiotics.

Authors:  B B Emerson; A L Smith; A L Harding; D H Smith
Journal:  J Pediatr       Date:  1975-04       Impact factor: 4.406

7.  Bactericidal activity and pharmacology of cefazolin.

Authors:  M G Bergeron; J L Brusch; M Barza; L Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

8.  Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Clinical studies of cefazolin and comparison with other cephalosporins.

Authors:  T Madhavan; E L Quinn; E Freimer; E J Fisher; F Cox; K Burch; D Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1973-11       Impact factor: 5.191

  9 in total
  7 in total

Review 1.  Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).

Authors:  Markus Zeitlinger; Markus Müller; Christian Joukhadar
Journal:  AAPS J       Date:  2005-10-22       Impact factor: 4.009

2.  Ascitic fluid cephalosporin concentrations: influence of protein binding and serum pharmacokinetics.

Authors:  D N Gerding; L R Peterson; D C Legler; W H Hall; E A Schierl
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

3.  Penetration and clearance of cefoperazone and moxalactam in pleural fluid.

Authors:  H Yamada; T Iwanaga; H Nakanishi; M Yamaguchi; K Iida
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

4.  Prediction of cefazolin penetration in high- and low-protein-containing extravascular fluid: new method for performing simultaneous studies.

Authors:  L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

5.  [Pharmacokinetic investigations on the penetration of mezlocillin into the pleural fluid].

Authors:  J Welter; D H Wittmann; H H Schassan
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 6.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

7.  Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis.

Authors:  Shashikant Srivastava; Tawanda Gumbo; Tania Thomas
Journal:  Front Pharmacol       Date:  2021-10-22       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.